The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Norby R Douglas since 2006.
The trader's CIK number is 1227001.
At the time of the last reporting, Norby R Douglas was the Director of Krystal Biotech, Inc.. (stock ticker symbol KRYS).
Also see all insider trading activities at Krystal Biotech, Inc..
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2006 | TSRA | 0 | $0 | 93,295 | $2,943,309 | 93,265 | $652,855 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2018 | KRYS | 9,000 | $93,780 | 0 | $0 | 0 | $0 |
| Insider Buying | Insider Sales | Option Exercises | |||||
|---|---|---|---|---|---|---|---|
| Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
| 2016 | ALXN | 0 | $0 | 0 | $0 | 15,500 | $2,022,409 |
| 2015 | ALXN | 0 | $0 | 45,442 | $8,524,601 | 0 | $0 |
| 2013 | ALXN | 0 | $0 | 40,000 | $4,089,720 | 40,000 | $577,000 |
| 2012 | ALXN | 0 | $0 | 52,000 | $4,596,283 | 55,115 | $418,870 |
| 2011 | ALXN | 0 | $0 | 68,000 | $5,128,390 | 68,000 | $401,502 |
| 2010 | ALXN | 0 | $0 | 0 | $0 | 3,965 | $0 |
| 2009 | ALXN | 0 | $0 | 86,000 | $3,448,760 | 84,000 | $1,814,705 |
| 2008 | ALXN | 0 | $0 | 2,000 | $123,160 | 0 | $0 |
1. Tessera Technologies Inc (TSRA)
2. Krystal Biotech, Inc. (KRYS)
3. Alexion Pharmaceuticals, Inc. (ALXN)
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2006-02-23 | TSRA | Option Ex | 60,781 | 7.00 | 425,467 |
| 2006-02-23 | TSRA | Sale | 60,781 | 32.44 | 1,971,735 |
| 2006-01-11 | TSRA | Sale | 27,930 | 30.11 | 840,944 |
| 2006-01-11 | TSRA | Option Ex | 27,900 | 7.00 | 195,300 |
| 2006-01-10 | TSRA | Sale | 4,584 | 28.50 | 130,630 |
| 2006-01-10 | TSRA | Option Ex | 4,584 | 7.00 | 32,088 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2018-05-09 | KRYS | Buy | 9,000 | 10.42 | 93,780 |
| Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
|---|---|---|---|---|---|
| 2016-09-23 | ALXN | Option Ex | 15,500 | 130.48 | 2,022,409 |
| 2015-12-11 | ALXN | Sale | 45,442 | 187.59 | 8,524,601 |
| 2013-05-22 | ALXN | Option Ex | 40,000 | 14.43 | 577,000 |
| 2013-05-22 | ALXN | Sale | 40,000 | 102.24 | 4,089,720 |
| 2012-12-10 | ALXN | Option Ex | 22,000 | 7.88 | 173,470 |
| 2012-12-10 | ALXN | Sale | 22,000 | 93.00 | 2,046,000 |
| 2012-03-09 | ALXN | Sale | 28,300 | 85.01 | 2,405,783 |
| 2012-03-08 | ALXN | Sale | 1,700 | 85.00 | 144,500 |
| 2012-03-09 | ALXN | Option Ex | 28,300 | 8.18 | 231,494 |
| 2012-03-08 | ALXN | Option Ex | 1,700 | 8.18 | 13,906 |
| 2012-02-03 | ALXN | Option Ex | 3,115 | .00 | 0 |
| 2011-10-28 | ALXN | Sale | 26,120 | 68.00 | 1,776,160 |
| 2011-10-27 | ALXN | Option Ex | 18,880 | 5.55 | 104,784 |
| 2011-10-28 | ALXN | Option Ex | 26,120 | 5.24 | 136,868 |
| 2011-10-27 | ALXN | Sale | 18,880 | 68.00 | 1,283,840 |
| 2011-02-14 | ALXN | Option Ex | 23,000 | 6.95 | 159,850 |
| 2011-02-14 | ALXN | Sale | 23,000 | 89.93 | 2,068,390 |
| 2010-01-28 | ALXN | Option Ex | 3,965 | .00 | 0 |
| 2009-11-03 | ALXN | Option Ex | 15,000 | 7.79 | 116,850 |
| 2009-11-03 | ALXN | Sale | 15,000 | 44.00 | 660,000 |
| 2009-08-24 | ALXN | Option Ex | 17,000 | 41.16 | 699,635 |
| 2009-08-24 | ALXN | Sale | 17,000 | 45.00 | 765,000 |
| 2009-08-04 | ALXN | Sale | 2,000 | 45.00 | 90,000 |
| 2009-08-04 | ALXN | Option Ex | 2,000 | 42.06 | 84,120 |
| 2009-06-19 | ALXN | Option Ex | 20,000 | 32.25 | 645,000 |
| 2009-06-19 | ALXN | Sale | 20,000 | 40.28 | 805,600 |
| 2009-03-16 | ALXN | Sale | 32,000 | 35.26 | 1,128,160 |
| 2009-03-16 | ALXN | Option Ex | 30,000 | 8.97 | 269,100 |
| 2008-02-20 | ALXN | Sale | 2,000 | 61.58 | 123,160 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Norby R Douglas (Director of Krystal Biotech, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.